nach oben

Erschienen in:

01.07.2009

Effect of Arsenic on Regulatory T Cells

verfasst von: B. Hernández-Castro, L. M. Doníz-Padilla, M. Salgado-Bustamante, D. Rocha, M. D. Ortiz-Pérez, M. E. Jiménez-Capdeville, D. P. Portales-Pérez, A. Quintanar-Stephano, R. González-Amaro

Erschienen in: Journal of Clinical Immunology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Arsenic (As) affects the function and survival of lymphocytes, and some arsenic compounds exert a relevant antineoplastic effect. We have explored the effect of As on T regulatory cells.

Results and Discussion

In vitro experiments with peripheral blood mononuclear cells from healthy subjects showed that low concentrations of As tended to increase the number of natural T regulatory (nTreg) lymphocytes, whereas concentrations >5.0 μM had an opposite effect. Furthermore, rats exposed to As showed redistribution of nTreg cells, and As administration to rats with experimental allergic encephalomyelitis increased the levels of nTreg cells in spleen and diminished the severity of this condition. On the other hand, in 47 apparently healthy subjects chronically exposed to As, we found significant inverse correlation between urinary As levels and the number and function of nTreg lymphocytes. Although most of these individuals showed enhanced levels of apoptotic lymphocytes in peripheral blood, with a diminution of mitochondrial membrane potential, no significant correlation between these parameters and urinary As was detected.

Conclusion

Our data indicate that As seems to have a relevant and complex effect on nTreg cells.

Stockinger B, Kassiotis G, Bourgeois C. Homeostasis and T cell regulation. Curr Opin Immunol. 2004;16:775–9. doi:10.1016/j.coi.2004.09.003.PubMedCrossRef

Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133:775–87. doi:10.1016/j.cell.2008.05.009.PubMedCrossRef

Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med. 2007;13:108–16. doi:10.1016/j.molmed.2007.01.003.PubMedCrossRef

Sakaguchi S, Ono M, Setoguchi R, et al. Foxp3⁺ CD25⁺ CD4⁺ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006;212:8–27. doi:10.1111/j.0105-2896.2006.00427.x.PubMedCrossRef

Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol. 2007;7:875–88. doi:10.1038/nri2189.PubMedCrossRef

Shevach EM. Regulatory/suppressor T cells in health and disease. Arthritis Rheum. 2004;50:2721–4. doi:10.1002/art.20500.PubMedCrossRef

Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol Rev. 2001;182:68–79. doi:10.1034/j.1600-065X.2001.1820105.x.PubMedCrossRef

Cortesini R, LeMaoult J, Ciubotariu R, Foca-Cortesini NS. CD8⁺CD28⁻ T suppressor cells and the induction of antigen-specific, antigen-presenting cell-mediated suppression of Th reactivity. Immunol Rev. 2001;182:201–6. doi:10.1034/j.1600-065X.2001.1820116.x.PubMedCrossRef

ATSDR. Toxicological profile for arsenic: agency for toxic substances and disease register. US, Atlanta GA: Department of Health & Human Services; 1999.

10.

Vega L, Ostrosky-Wegman P, Fortoul TI, Diaz C, Madrid V, Saavedra R. Sodium arsenite reduces proliferation of human activated T-cells by inhibition of the secretion of interleukin-2. Immunopharmacol Immunotoxicol. 1999;21:203–20. doi:10.3109/08923979909052758.PubMedCrossRef

11.

Soto-Peña GA, Luna AL, Acosta-Saavedra L, et al. Assessment of lymphocyte subpopulations and cytokine secretion in children exposed to arsenic. FASEB J. 2006;20:779–81.PubMed

12.

Conde P, Acosta-Saavedra LC, Gotilla-Acevedo RC, Calderón-Aranda ES. Sodium arsenite-induced inhibition of cell proliferation is related to inhibition of IL-2 mRNA expression in mouse activated T cells. Arch Toxicol. 2007;81:251–9. doi:10.1007/s00204-006-0152-7.PubMedCrossRef

13.

Pineda-Zavaleta AP, García-Vargas G, Borja-Aburto VH, et al. Nitric oxide and superoxide anion production in monocytes from children exposed to arsenic and lead in region Lagunera, Mexico. Toxicol Appl Pharmacol. 2004;198:283–90. doi:10.1016/j.taap.2003.10.034.PubMedCrossRef

14.

Smith AH, Hopenhayn-Rich C, Bates MN, et al. Cancer risks from Arsenic in drinking water. Environ Health Perspect. 1992;97:259–67. doi:10.2307/3431362.PubMedCrossRef

15.

Rossman TG. Mechanisms of arsenic carcinogenesis: an integrated approach. Mutat Res. 2003;533:37–65. doi:10.1016/j.mrfmmm.2003.07.009.PubMed

16.

Diaz Z, Mann KK, Marcoux S, et al. A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines. Leukemia. 2008;22:1853–63. doi:10.1038/leu.2008.194.PubMedCrossRef

17.

Litzow MR. Arsenic trioxide. Expert Opin Pharmacother. 2008;9:1773–85. doi:10.1517/14656566.9.10.1773.PubMedCrossRef

18.

de la Fuente H, Portales-Pérez D, Baranda L, et al. Effect of arsenic, cadmium and lead on the induction of apoptosis of normal human mononuclear cells. Clin Exp Immunol. 2002;129:69–77. doi:10.1046/j.1365-2249.2002.01885.x.PubMedCrossRef

19.

Wang SL, Chang FH, Liou SH, Wang HJ, Li WF, Hsieh DP. Inorganic arsenic exposure and its relation to metabolic syndrome in an industrial area of Taiwan. Environ Int. 2007;33:805–11. doi:10.1016/j.envint.2007.03.004.PubMedCrossRef

20.

Naithani R, Mahapatra M, Kumar R, Kumar A, Agrawal N. Arsenic trioxide induced acute flare-up of rheumatoid arthritis in a patient with APL. Ann Hematol. 2007;86:151–2. doi:10.1007/s00277-006-0208-z.PubMedCrossRef

21.

Navas-Acien A, Silbergeld EK, Pastor-Barriuso R, Guallar E. Arsenic exposure and prevalence of type 2 diabetes in US adults. JAMA. 2008;300:814–22. doi:10.1001/jama.300.7.814.PubMedCrossRef

22.

Vigna-Pérez M, Abud-Mendoza C, Portillo-Salazar H, et al. Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis. Clin Exp Immunol. 2005;141:372–80. doi:10.1111/j.1365-2249.2005.02859.x.PubMedCrossRef

23.

O’Connor RA, Anderton SM. Foxp3⁺ regulatory T cells in the control of experimental CNS autoimmune disease. J Neuroimmunol. 2008;193:1–11. doi:10.1016/j.jneuroim.2007.11.016.PubMedCrossRef

24.

Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6:295–307. doi:10.1038/nri1806.PubMedCrossRef

25.

Tone M, Tone Y, Adams E, et al. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci U S A. 2003;100:15059–64. doi:10.1073/pnas.2334901100.PubMedCrossRef

26.

Prieto GA, Rosenstein Y. Oestradiol potentiates the suppressive function of human CD4⁺CD25⁺ regulatory T cells by promoting their proliferation. Immunology. 2006;118:58–65. doi:10.1111/j.1365-2567.2006.02339.x.PubMedCrossRef

27.

Urzainqui A, Martínez del Hoyo G, Lamana A, et al. Functional role of P-selectin glycoprotein ligand 1/P-selectin interaction in the generation of tolerogenic dendritic cells. J Immunol. 2007;179:7457–65.PubMed

28.

Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther. 2006;8:R83. doi:10.1186/ar1954.PubMedCrossRef

29.

Quintana FJ, Basso AS, Iglesias AH, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature. 2008;453:65–71. doi:10.1038/nature06880.PubMedCrossRef

30.

Bobé P, Bonardelle D, Benihoud K, Opolon P, Chelbi-Alix MK. Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice. Blood. 2006;108:3967–75. doi:10.1182/blood-2006-04-020610.PubMedCrossRef

31.

Nadkarni S, Mauri C, Ehrenstein M. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med. 2007;204:33–9. doi:10.1084/jem.20061531.PubMedCrossRef

32.

Chen YZ, Wu Y, Huang MJ, Lu LH. Effect of endogenous TGF-beta1 and TNF-alpha on the As(2)O(3) inducing apoptosis of HL-60 cells. Zhonghua Xue Ye Xue Za Zhi. 2003;24:231–4.PubMed

33.

Yoshida T, Shimamura T, Shigeta S. Enhancement of the immune response in vitro by arsenic. Int J Immunopharmacol. 1987;9:411–5. doi:10.1016/0192-0561(87)90068-3.PubMedCrossRef

34.

Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF-alpha therapy. J Exp Med. 2004;200:277–85. doi:10.1084/jem.20040165.PubMedCrossRef

Titel: Effect of Arsenic on Regulatory T Cells
verfasst von: B. Hernández-Castro
L. M. Doníz-Padilla
M. Salgado-Bustamante
D. Rocha
M. D. Ortiz-Pérez
M. E. Jiménez-Capdeville
D. P. Portales-Pérez
A. Quintanar-Stephano
R. González-Amaro
Publikationsdatum: 01.07.2009
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 4/2009
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-009-9280-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Results and Discussion

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2009

Clinical and Molecular Characteristics of 35 Chinese Children with Wiskott–Aldrich Syndrome

Plasma 1,25 Dihydroxy Vitamin D3 Level and Expression of Vitamin D Receptor and Cathelicidin in Pulmonary Tuberculosis

ICOS Deficiency Results in Exacerbated IL-17 Mediated Experimental Autoimmune Encephalomyelitis

The Quality of Life of Children and Adolescents with X-Linked Agammaglobulinemia

Imbalances Between Interleukin-1 and Tumor Necrosis Factor Agonists and Antagonists in Stable COPD